EUVIMEDEUVIMED entdecken
Leitlinie

The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024)

P Kleiblová, J Novotný, D Cibula, V Curtisová, O Dubová, L Foretová, A Germanová, M Janatová, O Havránek, M Hojsáková, M Hudcová, M Koudová und 22 weitere

Klinicka onkologie · 2024

DOI: 10.48095/ccko2024292 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Klinicka onkologie, 2024. Verfasst von P Kleiblová und 33 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, BRCA2 Protein, Checkpoint Kinase 2, Fanconi Anemia Complementation Group N Protein.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia Telangiectasia Mutated ProteinsBRCA2 ProteinCheckpoint Kinase 2Fanconi Anemia Complementation Group N ProteinGenetic Predisposition to DiseaseGerm-Line MutationFemaleHumansMaleBRCA1 ProteinBreast NeoplasmsCzech RepublicOvarian NeoplasmsPancreatic NeoplasmsProstatic NeoplasmsPractice Guidelines as Topic

Stichwörter der Autor:innen

ATMBRCA1BRCA2CHEK2PALB2consensusgermline mutation carriersguidelines for clinical practice

Substanzen

Ataxia Telangiectasia Mutated ProteinsATM protein, humanBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCheckpoint Kinase 2CHEK2 protein, humanFanconi Anemia Complementation Group N ProteinPALB2 protein, human

Zitieren

APA

Kleiblová, P., Novotný, J., Cibula, D., Curtisová, V., Dubová, O., Foretová, L., Germanová, A., Janatová, M., Havránek, O., Hojsáková, M., Hudcová, M., Koudová, M., Krutílková, V., Palacova, M., Paulich, S., Petrakova, K., Presl, J., Puchmajerová, A., Soukupová, J., …, & Kleibl, Z. (2024). The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024). Klinicka onkologie. https://doi.org/10.48095/ccko2024292

Vancouver

Kleiblová P, Novotný J, Cibula D, Curtisová V, Dubová O, Foretová L, et al. The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024). Klinicka onkologie. 2024. doi:10.48095/ccko2024292

BibTeX
@article{Kleiblov2024,
  author = {Kleiblová, P and Novotný, J and Cibula, D and Curtisová, V and Dubová, O and Foretová, L and Germanová, A and Janatová, M and Havránek, O and Hojsáková, M and Hudcová, M and Koudová, M and Krutílková, V and Palacova, M and Paulich, S and Petrakova, K and Presl, J and Puchmajerová, A and Soukupová, J and Šenkeříková, M and Šimková, Z and Štěpánková, H and Šubrt, I and Tachecí, I and Tesner, P and Urban, O and Veselá, K and Vilímová, Š and Vlčková, Z and Vočka, M and Weinberger, V and Zikán, M and Zimovjanová, M and Kleibl, Z},
  title = {The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024)},
  journal = {Klinicka onkologie},
  year = {2024},
  doi = {10.48095/ccko2024292}
}
Kostenlos starten →